Literature DB >> 19398731

Cardiovascular risk and glycemic control.

Alice Y Y Cheng1, Lawrence A Leiter.   

Abstract

Mesh:

Substances:

Year:  2009        PMID: 19398731      PMCID: PMC2670896          DOI: 10.1503/cmaj.090252

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  10 in total

Review 1.  Insulin resistance and cardiovascular disease.

Authors:  S I McFarlane; M Banerji; J R Sowers
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

2.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

Authors:  David M Nathan; Patricia A Cleary; Jye-Yu C Backlund; Saul M Genuth; John M Lachin; Trevor J Orchard; Philip Raskin; Bernard Zinman
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

3.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

Authors:  Anushka Patel; Stephen MacMahon; John Chalmers; Bruce Neal; Laurent Billot; Mark Woodward; Michel Marre; Mark Cooper; Paul Glasziou; Diederick Grobbee; Pavel Hamet; Stephen Harrap; Simon Heller; Lisheng Liu; Giuseppe Mancia; Carl Erik Mogensen; Changyu Pan; Neil Poulter; Anthony Rodgers; Bryan Williams; Severine Bompoint; Bastiaan E de Galan; Rohina Joshi; Florence Travert
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

4.  10-year follow-up of intensive glucose control in type 2 diabetes.

Authors:  Rury R Holman; Sanjoy K Paul; M Angelyn Bethel; David R Matthews; H Andrew W Neil
Journal:  N Engl J Med       Date:  2008-09-10       Impact factor: 91.245

5.  Glucose control and vascular complications in veterans with type 2 diabetes.

Authors:  William Duckworth; Carlos Abraira; Thomas Moritz; Domenic Reda; Nicholas Emanuele; Peter D Reaven; Franklin J Zieve; Jennifer Marks; Stephen N Davis; Rodney Hayward; Stuart R Warren; Steven Goldman; Madeline McCarren; Mary Ellen Vitek; William G Henderson; Grant D Huang
Journal:  N Engl J Med       Date:  2008-12-17       Impact factor: 91.245

6.  Effect of interactions between C peptide levels and insulin treatment on clinical outcomes among patients with type 2 diabetes mellitus.

Authors:  Gary T C Ko; Wing-Yee So; Peter C Tong; Wing-Bun Chan; Xilin Yang; Ronald C Ma; Alice P Kong; Risa Ozaki; Chun-Yip Yeung; Chun-Chung Chow; Juliana C Chan
Journal:  CMAJ       Date:  2009-04-28       Impact factor: 8.262

7.  Effects of intensive glucose lowering in type 2 diabetes.

Authors:  Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

8.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

Authors:  Peter Gaede; Pernille Vedel; Nicolai Larsen; Gunnar V H Jensen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2003-01-30       Impact factor: 91.245

9.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Effect of a multifactorial intervention on mortality in type 2 diabetes.

Authors:  Peter Gaede; Henrik Lund-Andersen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2008-02-07       Impact factor: 91.245

  10 in total
  1 in total

1.  Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis.

Authors:  Ajay Chaudhuri; Julio Rosenstock; Andres DiGenio; Luigi Meneghini; Priscilla Hollander; Janet B McGill; Paresh Dandona; John Ilgenfritz; Matthew Riddle
Journal:  Diabetes Metab Res Rev       Date:  2012-03       Impact factor: 4.876

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.